UBC PiMS Research Group
Pharmacoepidemiology in Multiple Sclerosis Research Group

Afsaneh Shirani

Current Academic Status: Neurology Resident, University of Texas Southwestern Medical Center, Dallas, TX, USA 

Previous Academic Training: Postdoctoral Research Fellow (UBC) and MD (Tehran University of Medical Sciences, Iran)

Projects with PiMS group: Long-term Benefits and Adverse Effects of Beta-interferon for Multiple Sclerosis, Temporal Trends of Disability Progression in Patients with MS, Temporal Pattern of Demographic Changes in Patients with MS

Email: shirania@mail.ubc.ca

Awards Received:

  • Multiple Sclerosis Society of Canada Postdoctoral Fellowship
  • Consortium of Multiple Sclerosis Centers Scholarship Award
  • European Committee for Treatment and Research in Multiple Sclerosis Travel Awards
  • Multiple Sclerosis Society of Canada Travel Awards
  • Jacqueline Du Pre Award from Multiple Sclerosis International Federation 

 

Publications:

  • Shirani A, Zhao Y, Karim ME, Petkau J, Gustafson P, Evans C, Kingwell E, van der Kop ML, Oger J, Tremlett H. Investigation of heterogeneity in the association between interferon beta and disability progression in multiple sclerosis: an observational study. Eur J Neurol 2013 [Epub ahead of print].
  • Menon S, Shirani A, Zhao Y, Oger J, Traboulsee A, Freedman MS, Tremlett H. Characterising aggressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2013;84(11):1192-1198.
  • Shirani A, Zhao Y, Karim ME, Evans C, Kingwell E, van der Kop ML, Oger J, Gustafson P, Petkau J, Tremlett H. Interferon Beta and Long-term Disability in Multiple Sclerosis. JAMA Neurol 2013;70(5):651-3.
  • Lourenco P, Shirani A, Saeedi J, Oger J, Schreiber WE, Tremlett H. Oligoclonal bands and cerebrospinal fluid markers in multiple sclerosis: associations with disease course and progression. Mult Scler 2013;19(5):577-84.
  • Shirani A, Petkau J, Tremlett H. Authors’ reply to: Treatment with interferon beta for multiple sclerosis. JAMA 2012;308(16):1627-8.
  • Shirani A, Zhao Y, Karim ME, Evans C, Kingwell E, van der Kop ML, Oger J, Gustafson P, Petkau J, Tremlett H. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA 2012;18;308(3):247-56.
  • Shirani A, Zhao Y, Kingwell E, Rieckmann P, Tremlett H. Temporal trends of disability progression in multiple sclerosis: findings from British Columbia, Canada (1975-2009). Mult Scler 2012;18(4):442-50.
  • Shirani A, Tremlett H. The effect of smoking on the symptoms and progression of multiple sclerosis: a review. J Inflamm Res 2010,3:115-26.
  • Kingwell E, van der Kop M, Zhao Y, Shirani A, Zhu F, Oger J, Tremlett H. Relative mortality and survival in multiple sclerosis: Findings from British Columbia, Canada. J Neurol Neurosurg Psychiatry 2012;83(1):61-6.
  • Shahzadi S, Zali AR, Mohammadi AM, Abouzari M, Shirani A, Parsa K. Brain metastases in patients with diagnosed versus undiagnosed primary tumor. Neurosciences 2008;13 (3):268-71.
  • Amirjamshidi A, Abouzari M, Eftekhar B, Rashidi A, Rezaii J, Esfandiari K, Shirani A, Asadollahi M, Aleali H. Outcomes and recurrence rates in chronic subdural haematoma. Br J Neurosurg 2007;21(3):272-5.
  • Pakdaman H, Sahraian M, Fallah A, Pakdaman R, Ghareghozli K, Ghafarpour M, Rahimian E, Shirani A. Effect of early interferon beta-1a therapy on conversion to multiple sclerosis in Iranian patients with a first demyelinating event. Acta Neurol Scand 2007;115:429-431.
  • Harirchian MH, Sahraian MA, Shirani A. Serum prolactin level in patients with multiple sclerosis: a case control study. Med Sci Monit 2006;12(4):CR177-80.
  • Harirchian MH, Maghbooli M, Shirani A. A case of choreoacanthocytosis with marked weight loss: impact of orolingual dyskinesia. Neurol India 2006;54(3):296-7.

 

Conference Presentations/Abstracts:

  • Shirani A, Zhao Y, Oger J, BC MS Clinic Neurologists, Tremlett H. A comparison of extreme profiles of disability change in beta-interferon treated multiple sclerosis patients: findings from British Columbia, Canada. Mult Scler 2012; 18 (4 Suppl): 2-542. The 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Lyon, France. 10-13 October 2012.
  • Menon S, Zhu F, Shirani A, Oger J, Traboulsee A, Freedman M, BC MS Clinic Neurologists, Tremlett H. The natural history of aggressive multiple sclerosis: findings from British Columbia, Canada. Mult Scler 2012; 18 (4 Suppl): 2-542. The 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Lyon, France. 10-13 October 2012.
  • Karim MS, Gustafson P, Petkau J, Zhao Y, Shirani A, Evans C, Kingwell E, van der Kop ML, Tremlett H. A simulation study of the performance of the prescription time-distribution matching method to address immortal time bias. Joint Statistical Meeting, San Diego, CA, 28 July – 2 August 2012. Abstract #305129. In: JSM Proceedings, Statistics in Epidemiology Section. Alexandria, VA: American Statistical Association. August 2012.
  • Shirani A, Zhao Y, Oger J, Tremlett H. Changes in disability status in beta-inteferon treated multiple sclerosis patients:  a comparison of the extremes. Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) and American Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), San Diego, California, May 30 – June 2, 2012.
  • Menon S, Shirani A, Zhao Y, Sayao A-L, Tremlett T. Characterizing benign multiple sclerosis using age, disease duration and disability status in a longitudinal database. Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) and American Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), San Diego, California, May 30 – June 2, 2012.
  • Shirani A, Zhao Y, Kingwell E, Fisk J, Bhan V, Oger J, Tremlett H. Trends in age at onset of multiple sclerosis in two Canadian provinces: Importance of controlling for an equal observation time. In Proceedings of the 3rd Tykeson Fellows Conference, Dallas, Texas, 1-4 November, 2011.
  • Shirani A, Zhao Y, Kingwell E, Fisk J, Bhan V, Oger J, Tremlett H. Trends in age at onset of multiple sclerosis in two Canadian provinces: Importance of controlling for an equal observation time. Mult Scler 2011;17: S53–S276. The 5th Joint Triennial Congress of the European and Americas Committees on Treatment and Research in Multiple Sclerosis (ECTRIMS and ACTRIMS), Amsterdam, The Netherlands, 18-22 October, 2011.
  • Menon S, Shirani A, Zhao Y, Oger J, Traboulsee AL, Freedman MS, Tremlett H. Characteristics of aggressive multiple sclerosis: Findings from British Columbia, Canada.  Mult Scler 2011; 17: S277–S505. The 5th Joint Triennial Congress of the European and Americas Committees on Treatment and Research in Multiple Sclerosis (ECTRIMS and ACTRIMS), Amsterdam, The Netherlands, 18-22 October, 2011.
  • Shirani A. Trends in age at onset of MS: the biases are bad.The 1st Annual Retreat of the Pharmacoepidemiology in MS (PiMS) Research Group. Brain Research Center, UBC Hospital, University of British Columbia, Vancouver, BC, Canada. 20 September, 2011.
  • Karim ME, Gustafson P, Petkau J, Shirani A, van der Kop M, Kingwell E, Zhao Y, Evans C, Tremlett H. Marginal Structural Models for Investigating Long- Term Effectiveness of a Time-Dependent Treatment: An Application to Multiple Sclerosis. Joint Statistical Meeting, Miami, Florida, July 30 – August 4, 2011. Abstract #302665. In JSM Proceedings, Statistics in Epidemiology Section. Alexandria, VA: American Statistical Association. August 2011.
  • Shirani A, Zhao Y, Kingwell E, Rieckmann P, Tremlett H. Has disability progression in multiple sclerosis patients temporally changed? Can J Neurol Sci 2011; 38 (3) Suppl. 1: S26. Presented orally at the Canadian Neurological Sciences Federation’s 46th Annual Congress; Vancouver, BC, Canada, June 2011
  • Lourenco P, Shirani A, Saeedi J, Oger J, Schreiber W, Tremlett H. Oligoclonal banding and CSF markers in multiple sclerosis: associations with disease course and progression. UBC Medical Journal 2011; 2(2S): p. 16. The annual meeting of UBC Medicine Research Forum; Vancouver, BC, Canada, March 2011.
  • Lourenco P, Saeedi J, Shirani A, Oger J, Schreiber W, Tremlett H. Oligoclonal banding and cerebrospinal fluid markers in multiple sclerosis disease course and progression. Int J MS Care 2011; 13 Sppl. 3: 8. The 25th Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC), Montreal, QC, Canada, 1-4 June, 2011.
  • Shirani A, Zhao Y, Kingwell E, Rieckmann P, Tremlett H. No evidence for a temporal change in disability progression: findings from British Columbia, Canada (1975-2009). Presented orally at the endMS Conference 2010; Whistler, BC, Canada, December 2010.
  • Evans C, Zhao Y, Shirani A, Kingwell E, van der Kop ML, Karim ME, Gustafson P Petkau J, Tremlett H. The BeAMS Study: Long-term benefits and adverse effects of beta-interferons for multiple sclerosis: Impact on hospital services utilization. The endMS Conference 2010; Whistler, BC, Canada, December 2010.
  • Kingwell E, van der Kop M, Zhao Y, Shirani A, Oger J, Tremlett H. Mortality and predictors of survival in multiple sclerosis (MS): Findings from British Columbia, Canada. The endMS Conference 2010; Whistler, BC, Canada, December 2010.
  • Shirani A, Zhao Y, Kingwell E, Rieckmann P, Tremlett H. No evidence for temporal change in disability progression. Presented orally at the 7th International Congress on Multiple Sclerosis; Tehran, Iran, November 2010.
  • Shirani A, Zhao Y, Kingwell E, Rieckmann P, Tremlett H. No evidence for a temporal change in disability progression: findings from British Columbia, Canada (1975-2009). Mult Scler 2010; 16: S7-S39. Presented orally at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); Gothenburg, Sweden, October 2010.
  • Kingwell E, van der Kop M, Zhao Y, Shirani A, Rieckmann P, Tremlett H. Mortality and predictors of survival in multiple sclerosis (MS): Findings from British Columbia, Canada.  Multiple Sclerosis 2010; 16: S197-S352. The 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); Gothenburg, Sweden, October 2010.
  • Shirani A. No evidence for a temporal change in disability progression in multiple sclerosis: findings from British Columbia, Canada (1975-2009). Presented orally at the endMS Alberta Trainee Retreat, Kananaskis, Alberta, 18-19 September, 2010.
  • Shirani A. The rationale and design of ‘The BeAMS Study, Long-term Benefits and Adverse Effects of Beta-interferon for Multiple Sclerosis’. Presented orally at Oregon Health and Science University’s Multiple Sclerosis Forum for Trainees and Mentors, Bend, OR, USA, October 2009.
  • Shirani A. Soltanian-Zadeh H, Sahraian MA. Applications of artificial intelligence techniques in diagnosis and assessment of multiple sclerosis. Presented as a poster and published in the proceedings of the 5th International Multiple Sclerosis Congress of Iran, Tehran, Iran, November 2008.
  • Pakdaman H, Fallah A, Pakdaman R, Shirani A, Sahraian M. Impacts of early interferon beta1-a therapy on conversion to clinically definite multiple sclerosis in Iranian patients with a first demyelinating event. The 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Madrid, Spain, Sep. 2006. Mult Scler 2006; 12: S1-S228.
  • Shirani A, Sahraian MA, Harirchian MH, Mohebbi MR. Multiple sclerosis in Iran and the Middle East: new incidence trends and possible links. BMJ, June 2006. [Published online as rapid response]
  • Harirchian MH, Sahraian MA, Shirani A. Serum prolactin level in patients with multiple sclerosis: a case control study. The 10th Congress of the European Federation of Neurological Societies. Glasgow, UK, Sep. 2006. Eur J Neurol 2006;13(suppl 2):239.
  • Harirchian MH, Sahraian MA, Shirani A. Multiple sclerosis and hormones. Presented orally at the 10th Congress of Neurology and Electrophysiology. Tehran, Iran, May 2003. Iranian Journal of Neurology 2003;3(6):102-3.
  • Abolmaali K, Aghamohammadi A, Farhoudi A, Moein M, Pourpak Z, Rezaei N, Movahedi M, Gharagouzlou M, Mirsaeid Ghazi B, Atarod L, Ahmadi Afshar A, Abdollahpour H, Rafiei Samani F, Shirani A. The frequency of consanguinity in primary immunodeficient patients, registered in Iranian Primary Immunodeficiency Registry. The 21st Congress of the European Academy of Allergology and Clinical Immunology, 2002.

 

Published Books (in Persian Language):

  • Habibi G, Hamediseresht E, Shirani A, Heshmat R, Lotfollahi Shabestari O, Rahimi I, et al. Principles of Scientific Wriring. 2007, Marz-Fekr Publication, Tehran, Iran
  • Anoushiravani AA, Abbasi A, Shirani A, Hosseini M, Aloosh M, Shahi F. First Aid Endocrinology. 2004, Teimourzadeh Medical Publication, Tehran, Iran
  • Meysami F, Shirani A. Multiple choice questions on biology for high school students. 2000, Andishesazan Publication, Tehran, Iran.

a place of mind, The University of British Columbia

Pharmacoepidemiology in MS (PiMS)
2211 Wesbrook Mall,
Vancouver, BC, V6T 2B5, Canada
Email:

Emergency Procedures | Accessibility | Contact UBC  | © Copyright The University of British Columbia